Archive
Home / Media Centre / Archive
Here you can find the archive of all Press Releases prior to 2022
Filter by date:
Showing 1107 press releases before 2022
-
New Phase III data showed dapagliflozin significantly reduced HBA1C compared to placebo at 24 weeks in patients with type 2 diabetes inadequately controlled with the combination of metformin plus sulfonylurea
-
Fluenz Tetra, four-strain nasal spray vaccine, receives positive opinion in EU from CHMP for the prevention of seasonal influenza in children
-
FDA accepts new drug application for investigational compound Epanova for the treatment of severe hypertriglyceridaemia
-
US appeals court issues temporary injunction against Hanmi’s 505(b)2 NDA Esomeprazole Strontium
-
AstraZeneca and Merck enter licence agreement for investigational oral WEE1 kinase inhibitor therapy for cancer
-
AstraZeneca initiates Phase III clinical programme for olaparib, a treatment in development for patients with BRCA mutated ovarian cancer
-
ONGLYZA® (saxagliptin) achieves primary safety endpoint, demonstrating no increased risk for cardiovascular death, heart attack or stroke in SAVOR cardiovascular outcomes trial
-
MedImmune strengthens immune-mediated cancer therapy portfolio with acquisition of Amplimmune
-
AstraZeneca PLC second quarter and half year results 2013
-
AstraZeneca and FibroGen collaborate to develop and commercialise FG-4592, a treatment for anaemia in chronic kidney disease and end-stage renal disease
Latest articles and press releases
All of our latest press releases and articles are available to explore
